CC
RARE icon

Corton Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Corton Capital’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5,099
Closed -$283K – 591
2024
Q3 		$283K Buy
+5,099
New +$260K 0.14% 213
2023
Q4 		– Sell
-8,856
Closed -$316K – 636
2023
Q3 		$316K Buy
8,856
+2,794
+46% +$111K 0.16% 187
2023
Q2 		$280K Buy
+6,062
New +$281K 0.13% 230
2023
Q1 		– Sell
-6,017
Closed -$279K – 377
2022
Q4 		$279K Buy
+6,017
New +$237K 0.23% 141

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Corton Capital's RARE Position: Q4 2024 in Review

Corton Capital sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2024, closing a stake of 5,099 shares — an estimated $283K sold.

Corton Capital first reported a position in RARE in Q4 2022 and held it in 4 quarters. The position peaked at $316K in Q3 2023. 312 funds tracked by Wall St. Rank hold RARE as of Q4 2024.

  • Corton Capital reported no remaining Ultragenyx Pharmaceutical position as of Q4 2024 after selling out during the quarter.
  • Corton Capital sold 5,099 Ultragenyx Pharmaceutical shares in Q4 2024, an estimated $283K.
  • Corton Capital first reported a position in Ultragenyx Pharmaceutical in Q4 2022 and held it in 4 quarters.
  • Corton Capital's Ultragenyx Pharmaceutical position peaked at $316K in Q3 2023.
  • 312 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2024.

Based on Corton Capital's 13F filing for Q4 2024, filed 14 Feb 2025.